SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Syncom Formulations (India) submits reconciliation of share capital audit report

13 Jan 2023 Evaluate
With reference to the compliance of Regulation 76 of SEBI (Depositories and Participants) Regulations, 2018 (Previously known as Regulations 55A of SEBI (Depositories and Participants) Regulations 1996} & Circular No. D&CC/FITTC/CIR-16/2002 dated December 31st 2002 issued by SEBI, Syncom Formulations (India) has submitted Reconciliation of Share Capital Audit Report for the Quarter ended 31st December, 2022. The Reconciliation of Share Capital Audit Report will also be filed in XBRL mode within the stipulated time period.

The above information is a part of company’s filings submitted to BSE.

Syncom Formulations Share Price

13.67 -0.21 (-1.51%)
08-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1887.95
Dr. Reddys Labs. 1348.70
Cipla 1431.65
Zydus Lifesciences 1149.00
Lupin 2457.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: